XTL 6865
Alternative Names: Anti-HCV dual monoclonal antibody - XTL Biopharmaceuticals; HepeX-C; XTL-6865Latest Information Update: 01 Apr 2008
At a glance
- Originator XTL Biopharmaceuticals
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 29 Mar 2007 XTL 6865 is available for licensing worldwide (http://www.xtlbio.com)
- 29 Mar 2007 Results from a phase I clinical trial in patients with chronic hepatitis C added to the adverse events and pharmacokinetics sections
- 15 Aug 2006 XTL is continuing enrolment in a phase I trial for Hepatitis C infection in the US and Israel